Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial Clinical Impact Jun 3 Written By Frances Benson https://ir.arcellx.com/news/news-details/2022/Arcellx-Presents-Continued-Robust-Long-Term-Responses-from-its-CART-ddBCMA-Phase-1-Expansion-Trial-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma-at-the-2022-ASCO-Annual-Meeting/default.aspx 2022 Frances Benson
Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial Clinical Impact Jun 3 Written By Frances Benson https://ir.arcellx.com/news/news-details/2022/Arcellx-Presents-Continued-Robust-Long-Term-Responses-from-its-CART-ddBCMA-Phase-1-Expansion-Trial-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma-at-the-2022-ASCO-Annual-Meeting/default.aspx 2022 Frances Benson
